INHALANT USE DISORDER
What is inhalant use disorder? It is a problem that can develop when people deliberately breathe in the fumes of various substances, in order to experience intoxication. Basically, the disorder develops in people who frequently use inhalants as a recreational drug.
Overview from Wikipedia: Inhalant Use Disorder
Age Onset: Children and young teenagers.
Symptoms: Since the inhalants (even household chemicals) are heavier than oxygen when breathing, there is frequently brain damage or death through suffocation.
Causes: Specifically for inhaling glue, 38 U. S. states prohibit glue sales when inhaling is anticipated.
Youtube Video: Inhalant Use Disorder
Amazon or Library Book: Kids Who Use Inhalants
Amazon or Library Book:
A Manual of Inhalers, Inhallations and Inhalants
Click the book to link or order from Amazon.
Click the book to link or order from Amazon.
Support Group: SAMHSA.gov; 800-662-4357
(US Substance Abuse and Mental Halth Services Administration)
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Tailored Biologics Selection in Severe Asthmaby Sang Hyuk Kim on November 29, 2023
The management of severe asthma presents a significant challenge in asthma treatment. Over the past few decades, remarkable progress has been made in developing new treatments for asthma, primarily in the form of biological agents. These advances have been made possible through a deeper understanding of the underlying pathogenesis of asthma. Most biological agents focus on targeting specific inflammatory pathways known as type 2 inflammation. However, recent developments have introduced a new...
- The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reportsby Qing Song on November 29, 2023
CONCLUSION: Patients in Group A should be recommended to undergo mono-LAMA, while patients in Groups B and E should be recommended treatment with LABA + LAMA, which is consistent with the GOLD 2023 report. However, it is worth considering merging Groups A and C into a single group and recommending mono-LAMA as the initial inhalation therapy.
- Development of Novel Spray-Dried Microparticles to Treat Cystic Fibrosis: A Tri-Drug Approachby Vinayak D Kabra on November 29, 2023
CONCLUSION: Using spray-dried microparticles containing ciprofloxacin, ivacaftor, and L-salbutamol presents a novel approach to the treatment of cystic fibrosis.
- Clinical efficacy of budesonide combined with acetylcysteine in the treatment of mycoplasma pneumonia infectionby Jing Chen on November 29, 2023
CONCLUSION: Budesonide and N-acetylcysteine combination therapy in the treatment of MP infection in children has a significant effect, and can quickly relieve the clinical symptoms of children with good safety. It is worthy of widespread clinical use.